{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:21:32Z","timestamp":1787797292183,"version":"build-2784847793"},"reference-count":24,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Inflammatory cytokines may hold the key to the clinical evolution of psoriasis. The aims of this study are to find a correlation between levels of inflammatory cytokines such as TNF-\u03b1, IL-23, IL-17A, and IL-17F and disease duration and severity scores in psoriasis; to test if the decrease in any of the aforementioned cytokines is correlated with an amelioration in disease severity scores; and to analyze if any of the four biologic agents used are linked with a greater decrease in overall cytokine levels. We enrolled 23 adult patients under treatment with ixekizumab, secukinumab, guselkumab, or adalimumab and measured psoriasis disease severity scores PASI (Psoriasis Area Severity Index) and DLQI (Dermatology Life Quality Index), as well as the levels of the aforementioned cytokines at the start of therapy and after 3 months of continuous treatment. Inclusion criteria were the presence of psoriasis, age above 18 years and the need to initiate biological therapy (lack of response to standard treatment). Biological therapies resulted in an amelioration of PASI and DLQI scores, as well as levels of TNF-\u03b1, IL-23 and IL-17F. Disease duration and PASI and DLQI scores did not correlate with cytokine levels except DLQI and IL-23 score, in a paradoxically inversely proportional manner. IL-23, in particular, could be a useful biomarker for checking treatment response in psoriasis.<\/jats:p>","DOI":"10.3390\/cimb46070457","type":"journal-article","created":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T14:16:38Z","timestamp":1721398598000},"page":"7719-7729","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Inflammatory Cytokines and Clinical Outcome Following Biological Therapy in Adult Bio-Na\u00efve Psoriasis Patients"],"prefix":"10.3390","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4776-7247","authenticated-orcid":false,"given":"Teodora-Larisa","family":"Florian","sequence":"first","affiliation":[{"name":"Department of Physiology, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7730-338X","authenticated-orcid":false,"given":"Ioan-Alexandru","family":"Florian","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4549-3526","authenticated-orcid":false,"given":"Stefan Cristian","family":"Vesa","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, No. 23 Marinescu Street, 400337 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lehel","family":"Beni","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meda","family":"Or\u0103san","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Kim, H.O., Kang, S.Y., Kim, J.C., Park, C.W., and Chung, B.Y. (2021). Pediatric Psoriasis: From New Insights into Pathogenesis to Updates on Treatment. Biomedicines, 9.","DOI":"10.3390\/biomedicines9080940"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Mohd Noor, A.A., Azlan, M., and Mohd Redzwan, N. (2022). Orchestrated Cytokines Mediated by Biologics in Psoriasis and Its Mechanisms of Action. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020498"},{"key":"ref_3","first-page":"83","article-title":"Key Signaling Pathways in Psoriasis: Recent Insights from Antipsoriatic Therapeutics","volume":"11","author":"Johansen","year":"2021","journal-title":"Psoriasis (Auckland)"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.det.2014.09.002","article-title":"The immunopathogenesis of psoriasis","volume":"33","author":"Kim","year":"2015","journal-title":"Dermatol. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.1038\/ncomms6621","article-title":"The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis","volume":"5","author":"Lande","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e12945","DOI":"10.1111\/sji.12945","article-title":"Current knowledge on autoantigens and autoantibodies in psoriasis","volume":"92","author":"Petrovic","year":"2020","journal-title":"Scand. J. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nature06116","article-title":"Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide","volume":"449","author":"Lande","year":"2007","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1084\/jem.20090480","article-title":"Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8","volume":"206","author":"Ganguly","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_9","first-page":"S2","article-title":"Pathogenesis and treatment of psoriasis: Exploiting pathophysiological pathways for precision medicine","volume":"33","author":"Alwan","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/247553031319a00105","article-title":"Tumor necrosis factor-\u03b1 triad: Psoriasis, cardiovascular disease, and depression","volume":"19","author":"Leon","year":"2013","journal-title":"Psoriasis Forum."},{"key":"ref_11","first-page":"39","article-title":"Biologic Treatments of Psoriasis: An Update for the Clinician","volume":"15","author":"Brownstone","year":"2021","journal-title":"Biologics"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jdin.2022.08.008","article-title":"Cytokine Modulators in Plaque Psoriasis\u2014A Review of Current and Prospective Biologic Therapeutic Approaches","volume":"9","author":"Strychalski","year":"2022","journal-title":"JAAD Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s13555-021-00483-2","article-title":"Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities","volume":"11","author":"Menter","year":"2021","journal-title":"Dermatol. Ther. (Heidelb.)"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/2040622318759282","article-title":"Interleukin 23 in the skin: Role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment","volume":"9","author":"Chan","year":"2018","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_15","first-page":"1","article-title":"Targeting IL-23 in psoriasis: Current perspectives","volume":"8","author":"Fotiadou","year":"2018","journal-title":"Psoriasis (Auckland)"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e12725","DOI":"10.1111\/sji.12725","article-title":"Serum cytokine measurements and biological therapy of psoriasis\u2014Prospects for personalized treatment?","volume":"88","author":"Solberg","year":"2018","journal-title":"Scand. J. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1365-2133.2012.11038.x","article-title":"A comparison of serum inflammatory cytokines according to phenotype in patients with psoriasis","volume":"167","author":"Choe","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cyto.2015.10.004","article-title":"Serum levels of TWEAK in patients with psoriasis vulgaris","volume":"77","author":"Sivrikaya","year":"2016","journal-title":"Cytokine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00011-019-01238-8","article-title":"Proinflammatory and anti-inflammatory cytokine profiles in psoriasis: Use as laboratory biomarkers and disease predictors","volume":"68","author":"Cataldi","year":"2019","journal-title":"Inflamm. Res."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Kutwin, M., Migdalska-S\u0119k, M., Brzezia\u0144ska-Lasota, E., Zelga, P., and Wo\u017aniacka, A. (2021). An Analysis of IL-10, IL-17A, IL-17RA, IL-23A and IL-23R Expression and Their Correlation with Clinical Course in Patients with Psoriasis. J. Clin. Med., 10.","DOI":"10.3390\/jcm10245834"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/bjd.19018","article-title":"Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (\u22656 to <12 years of age): Efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study","volume":"183","author":"Philipp","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"705","DOI":"10.5114\/ada.2020.100481","article-title":"Interleukin 22 and 6 serum concentrations decrease under long-term biologic therapy in psoriasis","volume":"37","author":"Narbutt","year":"2020","journal-title":"Postep. Dermatol. Alergol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Andersen, C.S.B., Kvist-Hansen, A., Siewertsen, M., Enevold, C., Hansen, P.R., Kaur-Knudsen, D., Zachariae, C., Nielsen, C.H., Loft, N., and Skov, L. (2023). Blood Cell Biomarkers of Inflammation and Cytokine Levels as Predictors of Response to Biologics in Patients with Psoriasis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076111"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/exd.14582","article-title":"Ustekinumab reduces serum protein levels associated with cardiovascular risk in psoriasis vulgaris","volume":"31","author":"Koschitzky","year":"2022","journal-title":"Exp. Dermatol."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/46\/7\/457\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:19:38Z","timestamp":1760109578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/46\/7\/457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,19]]},"references-count":24,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["cimb46070457"],"URL":"https:\/\/doi.org\/10.3390\/cimb46070457","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,19]]}}}